INTRODUCTION AND OBJECTIVES: Serum biomarker monitoring is essential for management of germ-cell tumors(GCT). However, not all GCT are positive for conventional tumor markers. We examined whether serum N-glycan-based biomarkers can be applied for detection and prognosis in patients with GCT.
METHODS: We performed a comprehensive N-glycan structural analysis of sera from 54 untreated GCT patients and 103 ageadjusted healthy volunteers using glycoblotting methods and mass spectrometry. Candidate N-glycans were selected from those with the highest association; cutoff concentration values were established, and an N-glycan score was created based on the number of positive N-glycans present. The validity of this score for diagnosis and prognosis was analyzed using a receiver operating characteristic (ROC) curve. RESULTS: We identified 5 candidate N-glycans significantly associated with GCTpatients (A). The accuracy of the N-glycan score for GCT was significant with an area-under-the-curve (AUC) value of 0.87 (B). Diagnostically, the N-glycan score detected 10 of 12 (83%) patients with negative conventional tumor markers (C). Prognostically, the N-glycan score was comprised 4 candidate N-glycans (D). The predictive value of the prognostic N-glycan score was significant, with an AUC value of 0.89 (E). A high value prognostic N-glycan score was significantly associated with poor prognosis (F). Finally, to identify a potential carrier protein, immunoglobulin (Ig) fractions of sera were subjected to N-glycan analysis and compared to whole sera. Candidate N-glycans in Ig-fractions were significantly decreased; therefore, the carrier protein for candidate N-glycans is likely not an immunoglobulin.
CONCLUSIONS: Our newly developed N-glycan score seems to be a practical diagnostic and prognostic method for GCT.
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PD53-09 MEN WITH TESTICULAR CANCER HAVE LOWER SEMEN QUALITY COMPARED TO THOSE WITH OTHER MALIGNANCIES
Daisuke Noro*, Shingo Hatakeyama, Itsuto Hamano, Toshikazu Tanaka, Takuma Nairta, Tohru Yoneyama, Atsushi Imai, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama, Hirosaki, Japan INTRODUCTION AND OBJECTIVES: It is suggested that semen quality is already impaired in testicular cancer (TC) patients. However, the impact of type of malignancy on semen quality remains unclear. The aim of this study is to investigate the semen parameters and associated malignancies of men with cancer who cryopreserved sperm before undergoing therapy.
METHODS: We reviewed the database from our cryopreservation laboratory between January 1994 and May 2016, and identified 114 patients who have banked their sperm before undergoing treatment. Age at banking, semen volume, sperm density, percent motile sperm and type of cancer were recorded. Semen parameters were compared between TC and other malignancy (non-TC).
RESULTS: A total of 114 semen samples included 25% with testicular cancer (seminoma: 8.8% and non-seminoma: 17%), 25% with lymphoma, 18% with leukemia, 7.0% with myelodysplastic syndrome, 4.4% with solid cancer, 3.5% with urological cancer, 1.8% with immune system diseases, and unspecified 13%. Median patient age, semen volume, sperm Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1043
